Adicet Bio Inc (NAS:ACET)
$ 1.44 -0.03 (-2.04%) Market Cap: 118.32 Mil Enterprise Value: -18.00 Mil PE Ratio: 0 PB Ratio: 0.37 GF Score: 54/100

Adicet Bio Inc To Discuss Recent Data-Cut Date From Phase 1 Study Call Transcript

Dec 11, 2022 / 02:00PM GMT
Operator

Welcome to Adicet's specially scheduled Conference Call. This call is being recorded. At the end of the company's prepared remarks, we'll open the call for questions, and we'll provide specific instructions at that point.

I would now like to turn the call over to Anne Bowdidge. Please go ahead.

Anne Bowdidge

Good morning. Thank you for joining us. On the call today from Adicet are Chen Schor, President and CEO; Dr. Francesco Galimi, Chief Medical Officer; Nick Harvey, Chief Financial Officer; and Dr. Blake Aftab, Chief Scientific Officer. In addition, we're pleased to have Dr. Sattva Neelapu, Professor in the Department of Lymphoma/Myeloma at the University of Texas MD Anderson Cancer Center joining us today.

Before we begin, I'd like to remind you that various remarks that we make on this call contain forward-looking statements that are made under the safe harbor provisions of the securities laws, including, but not limited to, expressed or implied statements regarding the potential safety, durability, tolerability and efficacy of ADI-001, future

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot